Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398394 | 0.95 | MEN1 (0.52) | MEN1KMT2AEIF4EBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5411110 | 0.94 | MEN1 (0.47) | MEN1KMT2AEIF4EBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5410867 | 0.91 | NPC1 (0.46) | MEN1KMT2AEIF4EBP1SMN1; SMN2DPP4 | |
| SCHEMBL5402833 | 0.91 | AGTR1 (0.45) | MEN1KMT2AMAPK8PPARG | |
| SCHEMBL5415311 | 0.91 | KMT2A (0.43) | MEN1KMT2AEIF4EBP1P2RX3ALDH1A1 | |
| SCHEMBL5398897 | 0.90 | MEN1 (0.44) | MEN1KMT2AEIF4EBP1DPP4 | |
| SCHEMBL5418106 | 0.90 | MAPT (0.47) | MEN1KMT2AEIF4EBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5404381 | 0.89 | MEN1 (0.42) | MEN1KMT2AEIF4EBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5398717 | 0.89 | MEN1 (0.45) | MEN1KMT2ADPP4 | |
| SCHEMBL5395755 | 0.89 | TSHR (0.46) | MEN1KMT2AEIF4EBP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | MEN1 4216/4885KMT2A 3837/4885EIF4EBP1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.